Pentaerythritol tetranitrate
Tatkhimpharmpreparaty
1438 Items
2019-09-19
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Erinitis - venous vasodilator, has antianginal effect. Stimulates the formation of nitric oxide in the vascular wall, which is an endothelial relaxing factor. Erynite reduces preload (dilation of peripheral veins and reduction of blood flow to the right atrium) and afterload (OPS) on the heart; reduces myocardial oxygen demand. Restores blood flow in small endocardial vessels, improves in the epicardial coronary arteries, increases exercise tolerance in patients with coronary artery disease, angina pectoris. Reduces the pressure in the "small" circle of blood circulation. Compared with nitroglycerin, Erynite has a slower, but longer effect (up to 10 hours). When administered to the beginning of the effect - after 30-45 minutes (with sublingual - after 15-20 minutes), the duration is 4-5 hours.
Indications
IHD, stenocardia (prophylaxis, including in the post-infarction period); CHF (as part of complex therapy).
Composition
1 tablet contains pentaerythrityl tetranitrate 10 mg.
No customer reviews for the moment.
Dosage and Administration
Apply in / a (jet or drip), IV (jet or drip), IM, inside. Dose and treatment regimen are set individually.
Adverse reactions
From the side of the central nervous system: headache, dizziness; anxiety, sleep disorders; convulsions.
Dermatological reactions: hyperemia of the skin of the face, "flush" of blood to the skin of the face and upper chest, swelling, increased fragility of the nails.
From the digestive system: dry mouth, decreased appetite, intestinal atony, exacerbation of cholecystitis, cholestatic hepatitis, increased activity of hepatic transaminases and alkaline phosphatase.
On the part of the organ of vision: blurred vision, scotoma.
Since the cardiovascular system: tachycardia, arrhythmia, cardialgia, progression of angina, lower blood pressure.
From the hemopoietic system: thrombocytopenia, leukopenia, pancytopenia.
On the part of the blood coagulation system: hypofibrinogenemia; bleeding from the vessels of the skin, mucous membranes, stomach, intestines.
Allergic reactions: itching, skin flushing, urticaria, angioedema, anaphylactic shock.
Acute myocardial infarction, porphyria, massive bleeding, hemorrhagic stroke, retinal hemorrhage, pregnancy, lactation. For IV injection (optional) - arrhythmias, pronounced atherosclerosis of the coronary or cerebral arteries, uncontrolled arterial hypotension.
Contraindications
Hypersensitivity to pentoxifylline and other xanthine derivatives.
Drug interactions
Use with caution in the lability of blood pressure (a tendency to hypotension), chronic heart failure, gastric ulcer and duodenal ulcer (for ingestion), after recent surgery, with hepatic and / or renal failure, in children and adolescents under 18 years (efficacy and safety have not been studied).
In case of impaired renal function or severe hepatic impairment, correction of pentoxifylline dosing regimen is required.
During treatment, blood pressure should be monitored.
When used concomitantly with antihypertensive drugs, insulin, oral hypoglycemic drugs, it may be necessary to reduce the dose of pentoxifylline.
With simultaneous use with anticoagulants, blood clotting rates should be carefully monitored.
Pregnancy and Lactation
Adequate and well-controlled clinical studies on the safety of pentoxifylline in pregnancy have not been conducted.
Pentoxifylline and its metabolites are excreted in breast milk. If necessary, use during lactation should stop breastfeeding.
Special instructions
Use with caution in the lability of blood pressure (a tendency to hypotension), chronic heart failure, gastric ulcer and duodenal ulcer (for ingestion), after recent surgery, with hepatic and / or renal failure, in children and adolescents under 18 years (efficacy and safety have not been studied).
In case of impaired renal function or severe hepatic impairment, correction of pentoxifylline dosing regimen is required.
During treatment, blood pressure should be monitored.
When used concomitantly with antihypertensive drugs, insulin, oral hypoglycemic drugs, it may be necessary to reduce the dose of pentoxifylline.
With simultaneous use with anticoagulants should be closely monitored blood coagulation.
- Brand name: Erinite
- Active ingredient: Pentaerythritol tetranitrate
- Dosage form: Pills.
- Manufacturer: Tatkhimpharmpreparaty
- Country of Origin: Russia
Studies and clinical trials of Pentaerythritol tetranitrate (Click to expand)
- Spectroscopic and Thermal Studies on Pentaerythritol Tetranitrate (PETN)
- Asymmetric Reduction of Activated Alkenes by Pentaerythritol Tetranitrate Reductase: Specificity and Control of Stereochemical Outcome by Reaction Optimisation
- The Substrate Spectra of Pentaerythritol Tetranitrate Reductase, Morphinone Reductase, N-Ethylmaleimide Reductase and Estrogen-Binding Protein in the Asymmetric Bioreduction of Activated Alkenes
- Reproductive and developmental effects and physical and chemical properties of pentaerythritol tetranitrate (PETN) in the rat
- Focused Directed Evolution of Pentaerythritol Tetranitrate Reductase by Using Automated Anaerobic Kinetic Screening of Site-Saturated Libraries
- A Site-Saturated Mutagenesis Study of Pentaerythritol Tetranitrate Reductase Reveals that Residues 181 and 184 Influence Ligand Binding, Stereochemistry and Reactivity
- Inside Cover: Focused Directed Evolution of Pentaerythritol Tetranitrate Reductase by Using Automated Anaerobic Kinetic Screening of Site-Saturated Libraries (ChemBioChem 17/2010)
- Effect of zinc doping on pentaerythritol tetranitrate single crystals
- No evidence of toxicity or carcinogenicity of pentaerythritol tetranitrate given in the diet to F344 rats and B6C3F1 mice for up to two years
- The thermal decomposition of pentaerythritol tetranitrate, nitroglycerin, ethylenediamine dinitrate and ammonium nitrate
- Solubility of pentaerythritol tetranitrate-1,2-14C in water and saline
- Quantitative recovery of radioactivity from 14C-pentaerythritol tetranitrate administered to rats
- Pentaerythritol tetranitrate sustained-release tablets: Relation of in vitro release of the drug to blood pressure changes after administration to anesthetized cats
- Pharmacodynamics and biotransformation of pentaerythritol tetranitrate in man
- Simultaneous semiautomated determination of pentaerythritol tetranitrate or mannitol hexanitrate and phenobarbital in tablets
- Modified NF method for quantitative determination of pentaerythritol tetranitrate
- Validation of high-performance liquid chromatographic methods for analysis of sustained-release preparations containing nitroglycerin, isosorbide dinitrate, or pentaerythritol tetranitrate
- High-performance liquid chromatographic determination of the nitrate esters isosorbide dinitrate, pentaerythritol tetranitrate, and erythrityl tetranitrate in various tablet forms
- Pharmacokinetics of pentaerythritol tetranitrate following intra-arterial and oral dosing in the rat
- Fracture-induced decomposition of a brittle high explosive: Pentaerythritol tetranitrate
- Thermal analysis of some crystal habits of pentaerythritol tetranitrate
- Thermal decomposition of mixtures containing nitrocellulose and pentaerythritol tetranitrate
- Application of isothermal calorimetry and UV spectroscopy for stability monitoring of pentaerythritol tetranitrate
- Periodic Hartree–Fock study of the elasticity of pentaerythritol tetranitrate
Customers who bought this product also bought:
8 other products in the same category:
arrow_upward